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thromboses that cause a transient ischemic attack (TIA) or stroke have
only been reported in association with underlying lung neoplasia [5],
previous pulmonary transplant or lobectomy [6] and pulmonary arte-
riovenous malformations or ﬁstulae [7].
Since 2012, I have published several cases of pulmonary vein throm-
boses in elderly patients without these conditions, such as lung cancer
and lung surgery, using 64-MDCT, which can evaluate coronary artery
stenosis and the pulmonary vein thrombi (8,9) simultaneously. It was
reported that a small pulmonary vein thrombus might originate from
a larger pulmonary vein thrombus [8]. Recently, I reported that nearly1. Introduction
Stroke is an increasing health problem throughout the world in
the elderly populations and has become one of the major causes of
mortality. The onset of ischemic stroke is sudden and can result in either
temporary or permanent brain damage. Additionally, stroke is an im-
portant contributor to dementia and age-related cognitive decline and
is frequently associated with permanent disability and impaired quality
of life [1]. Although conventional risk factors such as hypertension ac-
count for a signiﬁcant proportion of stroke risk, the inﬂuence of many
other factors remains unclear [2].
Stroke riskmodiﬁcation and strokeprevention aremajor focal points
in health care. Primary and secondary strokeprevention strategies differ
according to stroke subtype; however, there is no direct method to
evaluate the efﬁciency of anticoagulants. In 2015, Marcucci R. asked
whether we can estimate the resistance of antiplatelet drugs [3], to
which I responded that a 64-slice multidetector computed tomography
(64-MDCT) may estimate the resistance of antiplatelet drugs by means
of estimating the size of a pulmonary vein thrombus in elderly patients
with chest pain [4].DCT in assessing patients with
onsideration for use in day-to-
and Ltd. This is an open access articlePulmonary vein thromboses are thought to be rare. Pulmonary vein
all left atrial thrombi are alleged to arise from a pulmonary vein throm-
bus [9].
Warfarin, the predominant anticoagulant in clinical use, has been
shown to reduce AF-related stroke by 64% in a large meta-analysis
[10]. Although I reported that warfarin and dabigatran dissolved a large
pulmonary vein thrombus that was not completely occluded, it is unclear
whether warfarin and dabigatran could dissolve a small thrombus that
completely occluded the pulmonary vein. However, the direct effects of
warfarin therapy on a completely occluded small thrombus in a small pul-
monary vein have not been thoroughly characterized.
2. Case reports
2.1. Case 1
A 77-year-oldmale with a lacuna infarction in the ponswas referred
to our hospital to evaluate a source of cerebral infarction. He had no
atrial ﬁbrillation (AF). He was treated with aspirin (82 mg once daily),
and no previous treatment with warfarin or NOACs had been imple-
mented. A 64-MDCT scan showed a 3 to 4mmthrombus at the proximal
side of the right upper pulmonary vein (Fig. 1A and B; axial). After
2 months of warfarin therapy, the thrombus disappeared (Fig. 1C and
D; axial). Concurrently, a ﬁne vessel could be identiﬁed at the base of
the eliminated thrombus, indicating thatwarfarin dissolved a complete-
ly occluded thrombus.
2.2. Case 2
A 74-year-old male with AF was referred to our hospital for the
evaluation of an LAA thrombus. No previous treatment with warfarinunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A B
C D
RUPV
RUPVRUPV
RUPV
LA
LALA
LA
Fig. 1. (A, B) Axial images showing a thrombus (3 to 4 mm) within the right upper pulmonary vein (arrowhead) before warfarin therapy. (C, D) Axial images showing the distinguished
thrombuswithin the right upper pulmonary vein after 2months of warfarin therapy. Simultaneously, a small vessel appeared at the base of the eliminated thrombus (yellow arrowhead).
RUPV: right upper pulmonary vein, LA: left atrium.
147H. Takeuchi / IJC Heart & Vasculature 7 (2015) 146–148had been performed because the patient rejected the therapy. The
patient had no symptoms of lung cancer or cerebral infarction. The
chest roentgenogram showed no lung cancer. Large thrombiwere detect-
ed in the right upper pulmonary vein, the left upper pulmonary vein and
the left atrium(LA), as shown in axial (Fig. 1A toD) images as thedefect of
an enhancement by a 64-MDCT scan. Themerge of a thrombuswas sharp
(Fig. 1A and B), and part of the thrombus could be observed in the LA
(Fig. 1D). After 3 months of warfarin therapy, the size of the thrombi
did not appear to change signiﬁcantly; however, the shape of the thrombi
appeared to change (Fig. 2E to G). In Fig. 2E and F, the sharp borderline
became vague. In Fig. 2H, the size of the thrombi in LA appeared toA B
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Fig. 2. Axial images showing thrombi within the right upper and the left upper pulmonary vei
enlarged defects because of large thrombi (Fig. 2A). The left upper pulmonary vein demonstra
in left atrium was vague (Fig. 2C and 2D). After 3 months of warfarin therapy, the size of the t
2G). In Fig. 2E and Fig. 2F, the sharp borderline disappeared and became rather vague (yellow
“lines” (yellow arrowheads). DAo: descending aorta, LUPV: left upper pulmonary vein, RUPV:be reduced, which is depicted as “lines.” During the warfarin thera-
py, the patient had no symptoms of systemic thrombosis such as ce-
rebral infarction.
3. Discussion
In the ﬁrst case, warfarin dissolved a small, completely occluded
thrombus in the small pulmonary vein after 2 months of therapy. In
the second case, warfarin did not signiﬁcantly dissolve a large thrombus
in the pulmonary vein by 3-month therapy; however, the thrombus
in the left atrium decreased in size. Additionally, the shape of theC D
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ns (white arrowheads). The right upper and the left upper pulmonary veins present with
ted the sharp merge of enhancement (Fig. 2A and 2B), whereas the merge of the thrombi
hrombi did not change signiﬁcantly, but the shape of the thrombi was altered (Fig. 2E to
arrowhead). In Fig. 2H, the image size of thrombi in the LA decreased, which is shown as
right upper pulmonary vein.
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the thrombus in the left upper pulmonary veinwas sharp; after 3months
ofwarfarin therapy, themerge of the thrombus becamevague, suggesting
that warfarin gradually dissolved the thrombus. One reason why the
thrombus in the left atrium dissolved might be the high volume of
warfarin-treated blood ﬂow. The use of 64-MDCT scans could assess
the thrombus in the pulmonary vein and the left atrium. This is the
ﬁrst case study to demonstrate not only the dissolution of a small
thrombus in the pulmonary vein, but the appearance of the small vessel
after warfarin therapy at the original thrombus site, which might be the
root of the dissolved thrombus. I have reported that nearly all of a
left atrial thrombus was rooted from a pulmonary vein thrombus
[8]. In another case, the round thrombus in the right upper pulmonary
vein had a small thrombus in the small vessel, which connected to the
thrombus as a root [9].
Althoughwarfarinwasunable to intercalate into the large thrombus,
the treatmentwas successful in dissolving themerge of the large throm-
bus. However, when the thrombus is small, warfarin could dissolve the
thrombus as shown in the ﬁrst case, which was illustrated using 64-
MDCT scans. It is thus important to recognize the capabilities of 64-
MDCT scans in treating pulmonary vein thrombi.
When the pulmonary vein or a branch of the pulmonary vein
is completely occluded by a thrombus, the blood ﬂow decreases, which
causes hypoxic, undernourished tissue as well as a reduced temperature.
Hypoxia activates hypoxia inducible factors (HIFs), and malnourishment
induces the expression of metal-regulatory transcription factor-1 (MTF-
1) andnuclear respiratory factor-1 and -2 (NRF-1, -2). Low tissue temper-
ature may modulate heat shock protein (HSP) expression by unknown
mechanism(s). These transcription factors can cause epigenetic changes
in associated cells. Abnormal function of HSP, which is caused by pulmo-
nary vein thrombosis, may play roles in elderly patients with pulmonary
diseases such as lung cancer, chronic obstructive pulmonary disease
or atrial ﬁbrillation (AF). According to thismanuscript, warfarin dissolved
the completely occluded thrombus in the ﬁne pulmonary vein. I have re-
ported that dabigatran was able to almost entirely dissolve a pulmonary
vein thrombus. Although warfarin and dabigatran have been usedclinically in patients with AF and have been shown to dissolve a pulmo-
nary vein thrombus to someextent, there is little evidence that such treat-
ment cured the AF, indicating that the recovery of arterial blood ﬂowdoes
not cure the induced epigenetic changes of the associated cells. More
studies are required to obtain insight into novel therapies to cure AF
after dissolving a completely occluded thrombus in the pulmonary vein.Conﬂict of interest
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